Commensal Bacteria Strains

Phase 1Biologic

UUniversity of Chicago

Commensal Bacteria Strains is one of 4 biologic programs targeting Microbiota. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MicrobiotaRecruiting

MicrobiotaPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Microbiota

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 2

1 2

Taxol

Teva

Phase 2

1 3

Carboplatin AUC-5

Merck & Co.

Phase 2

1 4

Commensal Bacteria Strains

UUniversity of Chicago

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Microbiota

NCT06871111

Clinical

Trials by Indication[1]

Microbiota1 trial

The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial

Recruiting·UUniversity of Chicago·Phase 1·NCT06871111·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Commensal Bacteria Strains. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Commensal Bacteria Strains compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Commensal Bacteria Strains. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Chicago company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Chicago

Commensal Bacteria Strains

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Microbiota1 trial

References

Drug Info

Quick Facts

Related News